- Home
- BLRX vs AQMS Comparison
BLRX vs AQMS Comparison
Compare BLRX & AQMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- AQMS
- Stock Information
- Founded
- BLRX 2003
- AQMS 2014
- Country
- BLRX Israel
- AQMS United States
- Employees
- BLRX N/A
- AQMS N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- AQMS Metal Fabrications
- Sector
- BLRX Health Care
- AQMS Industrials
- Exchange
- BLRX Nasdaq
- AQMS Nasdaq
- Market Cap
- BLRX 12.2M
- AQMS 13.7M
- IPO Year
- BLRX 2011
- AQMS 2015
- Fundamental
- Price
- BLRX $3.10
- AQMS $1.76
- Analyst Decision
- BLRX Buy
- AQMS Strong Buy
- Analyst Count
- BLRX 2
- AQMS 3
- Target Price
- BLRX $26.00
- AQMS $21.00
- AVG Volume (30 Days)
- BLRX 26.4K
- AQMS 48.2K
- Earning Date
- BLRX 05-27-2025
- AQMS 05-14-2025
- Dividend Yield
- BLRX N/A
- AQMS N/A
- EPS Growth
- BLRX N/A
- AQMS N/A
- EPS
- BLRX N/A
- AQMS N/A
- Revenue
- BLRX $28,940,000.00
- AQMS N/A
- Revenue This Year
- BLRX N/A
- AQMS N/A
- Revenue Next Year
- BLRX N/A
- AQMS $550.00
- P/E Ratio
- BLRX N/A
- AQMS N/A
- Revenue Growth
- BLRX 502.92
- AQMS N/A
- 52 Week Low
- BLRX $2.85
- AQMS $1.33
- 52 Week High
- BLRX $35.60
- AQMS $13.78
- Technical
- Relative Strength Index (RSI)
- BLRX 41.70
- AQMS 40.07
- Support Level
- BLRX $3.01
- AQMS $1.89
- Resistance Level
- BLRX $3.61
- AQMS $2.10
- Average True Range (ATR)
- BLRX 0.22
- AQMS 0.16
- MACD
- BLRX 0.02
- AQMS -0.02
- Stochastic Oscillator
- BLRX 32.89
- AQMS 4.64
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.